Edgewise Therapeutics, Inc.(EWTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

EWTX Edgewise Therapeutics, Inc.

Not Yet Opened 08-25 16:00:00 EDT

44.21

-0.51

-1.14%

盘后44.21

+0.000.00%

19:30 EDT

High46.32	Low44.02	Vol1.15M
Open45.22	D1 Closing44.72	Amplitude5.14%
Mkt Cap4.80B	Tradable Cap3.90B	Total Shares108.60M
T/O51.47M	T/O Rate1.30%	Tradable Shares88.17M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"EWTX","market":"US","secType":"STK","nameCN":"Edgewise Therapeutics, Inc.","latestPrice":44.21,"timestamp":1787688000000,"preClose":44.72,"halted":0,"volume":1149211,"hourTrading":{"tag":"盘后","latestPrice":44.21,"preClose":44.21,"latestTime":"19:30 EDT","volume":102188,"amount":4517736.92,"timestamp":1787700602211,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.011404293381037522,"floatShares":88170878,"shares":108604129,"eps":-1.850165,"marketStatus":"Not Yet Opened","change":-0.51,"latestTime":"08-25 16:00:00 EDT","open":45.22,"high":46.32,"low":44.02,"amount":51465472.46841,"amplitude":0.051431,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.850165,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787731200000},"marketStatusCode":0,"adr":0,"listingDate":1616731200000,"exchange":"NASDAQ","adjPreClose":44.72,"preHourTrading":{"tag":"盘前","latestPrice":45.3,"preClose":44.72,"latestTime":"09:13 EDT","volume":482,"amount":21597.183188,"timestamp":1787663607195,"change":0.58,"changeRate":0.01297,"amplitude":0.023256},"postHourTrading":{"tag":"盘后","latestPrice":44.21,"preClose":44.21,"latestTime":"19:30 EDT","volume":102188,"amount":4517736.92,"timestamp":1787700602211,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.777865,"impliedVol":0.7531,"impliedVolPercentile":0.56},"requestUrl":"/m/hq/s/EWTX/tweets","defaultTab":"tweets","newsList":[{"id":"2661276378","title":"Edgewise Says Phase 2 Cirrus-HCM Trial Shows Positive Top-Line Data for EDG-7500 in Hypertrophic Cardiomyopathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2661276378","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661276378?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:02","pubTimestamp":1787572938,"startTime":"0","endTime":"0","summary":"Edgewise says Phase 2 CIRRUS-HCM trial shows positive top-line data for EDG-7500 in hypertrophic cardiomyopathyEdgewise Therapeutics flagged positive top-line results from its 12-week Phase 2 CIRRUS-H","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL5MQ07j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661252375","title":"Egetis Bolsters Finances and IP as Emcitate Nears Key FDA Decision","url":"https://stock-news.laohu8.com/highlight/detail?id=2661252375","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661252375?lang=en_us&edition=fundamental","pubTime":"2026-08-21 13:33","pubTimestamp":1787290381,"startTime":"0","endTime":"0","summary":"Egetis Therapeutics AB ( ($SE:EGTX) ) has provided an update. Egetis Therapeutics reported second-quarter 2026 net revenue of SEK 17.4 million from...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/egetis-bolsters-finances-and-ip-as-emcitate-nears-key-fda-decision?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/egetis-bolsters-finances-and-ip-as-emcitate-nears-key-fda-decision?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","EWTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661239730","title":"Edgewise Therapeutics Price Target Raised to $60.00/Share from $53.00 by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2661239730","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661239730?lang=en_us&edition=fundamental","pubTime":"2026-08-21 02:05","pubTimestamp":1787249100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EWTX/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660289321","title":"Edgewise Therapeutics price target raised to $60 from $53 at JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2660289321","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660289321?lang=en_us&edition=fundamental","pubTime":"2026-08-20 19:20","pubTimestamp":1787224854,"startTime":"0","endTime":"0","summary":"JPMorgan raised the firm’s price target on Edgewise Therapeutics (EWTX) to $60 from $53 and keeps an Overweight rating on the shares. The firm upda...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/edgewise-therapeutics-price-target-raised-to-60-from-53-at-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/edgewise-therapeutics-price-target-raised-to-60-from-53-at-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRTO","EWTX","PGF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660406372","title":"Edgewise Therapeutics (EWTX) Is Up 6.6% After Wider Q2 Losses Highlight Rising Spend - Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2660406372","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660406372?lang=en_us&edition=fundamental","pubTime":"2026-08-20 13:28","pubTimestamp":1787203731,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics, Inc. reported second-quarter 2026 results showing a net loss of US$57.33 million and basic loss per share of US$0.53, with first-half 2026 net loss reaching US$106.34 million and loss per share of US$0.99, both higher than the same periods a year earlier.\nThe widening losses highlight the company’s increasing spending relative to its current revenue base, which will be central to assessing its financial trajectory and funding needs.\nNext, we will examine how the...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ewtx/edgewise-therapeutics/news/edgewise-therapeutics-ewtx-is-up-66-after-wider-q2-losses-hi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ewtx/edgewise-therapeutics/news/edgewise-therapeutics-ewtx-is-up-66-after-wider-q2-losses-hi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["EWTX","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660096101","title":"Edgewise Therapeutics (EWTX) Reports Wider Losses On A Valuation That Still Looks Rich","url":"https://stock-news.laohu8.com/highlight/detail?id=2660096101","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660096101?lang=en_us&edition=fundamental","pubTime":"2026-08-17 09:25","pubTimestamp":1786929928,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics (EWTX) recently reported second quarter 2026 results that showed a wider net loss of $57.33 million and a basic loss per share of $0.53, compared with the prior year period.\nSee our latest analysis for Edgewise Therapeutics.\nDespite the wider loss, Edgewise Therapeutics shares have shown strong momentum, with a 30 day share price return of 11.09% and an 85.98% year to date share price return. The 1 year total shareholder return of 212.16% and 3 year total shareholder...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ewtx/edgewise-therapeutics/news/edgewise-therapeutics-ewtx-reports-wider-losses-on-a-valuati","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ewtx/edgewise-therapeutics/news/edgewise-therapeutics-ewtx-reports-wider-losses-on-a-valuati","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4539","BK4007","EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659121925","title":"Edgewise Therapeutics CMO Joanne M. Donovan Disposes of USD 411,192 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2659121925","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659121925?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:57","pubTimestamp":1786741070,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics CMO Joanne M. Donovan disposes of USD 411,192 in common sharesEdgewise Therapeutics CMO Joanne M. Donovan reported RSU vesting on Aug. 12, 2026, adding 12,812 common shares.Sold ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL45dswq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Edgewise Therapeutics CMO Joanne M. Donovan Disposes of USD 411,192 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658917581","title":"Edgewise Therapeutics is Maintained at Neutral by Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2658917581","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658917581?lang=en_us&edition=fundamental","pubTime":"2026-08-12 02:02","pubTimestamp":1786471320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EWTX/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658575991","title":"Edgewise Therapeutics price target raised to $36 from $32 at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2658575991","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658575991?lang=en_us&edition=fundamental","pubTime":"2026-08-11 18:15","pubTimestamp":1786443327,"startTime":"0","endTime":"0","summary":"Goldman Sachs raised the firm’s price target on Edgewise Therapeutics (EWTX) to $36 from $32 and keeps a Neutral rating on the shares. Published fi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/edgewise-therapeutics-price-target-raised-to-36-from-32-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/edgewise-therapeutics-price-target-raised-to-36-from-32-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657614018","title":"Wedbush Adjusts Pt on Edgewise Therapeutics to $53 From $52, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2657614018","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657614018?lang=en_us&edition=fundamental","pubTime":"2026-08-07 18:08","pubTimestamp":1786097303,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics (EWTX) has an average rating of buy and mean price target of $50.46, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657637528","title":"Edgewise Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657637528","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657637528?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:47","pubTimestamp":1786024049,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryEdgewise Therapeutics IncEWTX.OQreported a quarterly adjusted loss of 53 cents per share for the quarter ended","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N44321W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657314326","title":"Edgewise Therapeutics Q2 EPS $(0.53) Misses $(0.47) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657314326","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657314326?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:45","pubTimestamp":1786020304,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.47) by 12.77 percent. This is a 55.88 percent decrease over losses of $(0.34) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60993924/edgewise-therapeutics-q2-eps-0-53-misses-0-47-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657572639","title":"Edgewise Therapeutics Q2 Operating Income USD -61.943 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657572639","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657572639?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:13","pubTimestamp":1786018417,"startTime":"0","endTime":"0","summary":"Aug 06 (Reuters) - Edgewise Therapeutics Q2 operating expenses USD 61.943 million.:((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))Source Date/Time = 06-AUG-202612:01:03.517 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nRSD2yXCDW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","EWTX","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657639830","title":"Edgewise Net Loss Widens 58.74% to $57.33 Million in Q2 FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2657639830","media":"Reuters","labels":["event","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657639830?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:08","pubTimestamp":1786018133,"startTime":"0","endTime":"0","summary":"Edgewise net loss widens 58.74% to $57.33 million in Q2 FY26Edgewise Therapeutics posted a GAAP net loss of $57.33 million, or $0.53 per share, for Q2 2026.R&D expense climbed to $47.55 million from $","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL8DMLVC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","EWTX","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657636992","title":"Edgewise Therapeutics Q2 Operating Expenses USD 61.943 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657636992","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657636992?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:00","pubTimestamp":1786017603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXBT69B9:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EWTX","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657636639","title":"Edgewise Therapeutics Q2 Basic EPS USD -0.53","url":"https://stock-news.laohu8.com/highlight/detail?id=2657636639","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657636639?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:00","pubTimestamp":1786017603,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXBT69B9:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","EWTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657460636","title":"Press Release: Edgewise Therapeutics Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2657460636","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657460636?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:00","pubTimestamp":1786017600,"startTime":"0","endTime":"0","summary":"--  Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) ----  Completed sale of sevasemten and musc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HYLG","BMED","BK4531","GDOC","HCM","BK4539","BK4585","NVIB","IDNA","BK4007","MEDX","EWTX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657619529","title":"Edgewise’s EDG-15400 Phase 1 Milestone: What It Means for EWTX Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2657619529","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657619529?lang=en_us&edition=fundamental","pubTime":"2026-08-06 00:30","pubTimestamp":1785947425,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics, Inc. ($EWTX) announced an update on their ongoing clinical study. Edgewise Therapeutics, Inc. is running a Phase 1 study cal...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/edgewises-edg-15400-phase-1-milestone-what-it-means-for-ewtx-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/edgewises-edg-15400-phase-1-milestone-what-it-means-for-ewtx-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ISBC","EWTX","BK4007","BK4211","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652163432","title":"Edgewise Therapeutics is Maintained at Outperform by Evercore ISI Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2652163432","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652163432?lang=en_us&edition=fundamental","pubTime":"2026-07-20 21:07","pubTimestamp":1784552820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EWTX/analyst-ratings(END) Dow Jones NewswiresJuly 20, 2026 09:07 ET","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652215014","title":"Edgewise Therapeutics price target raised to $55 from $45 at Evercore ISI","url":"https://stock-news.laohu8.com/highlight/detail?id=2652215014","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652215014?lang=en_us&edition=fundamental","pubTime":"2026-07-20 20:50","pubTimestamp":1784551822,"startTime":"0","endTime":"0","summary":"Evercore ISI analyst Cory Kasimov raised the firm’s price target on Edgewise Therapeutics (EWTX) to $55 from $45 and keeps an Outperform rating on ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/edgewise-therapeutics-price-target-raised-to-55-from-45-at-evercore-isi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/edgewise-therapeutics-price-target-raised-to-55-from-45-at-evercore-isi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EWTX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.edgewisetx.com","stockEarnings":[{"period":"1week","weight":0.0023},{"period":"1month","weight":0.0825},{"period":"3month","weight":0.3181},{"period":"6month","weight":0.4906},{"period":"1year","weight":2.0916},{"period":"ytd","weight":0.7816}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0365},{"period":"3month","weight":0.0206},{"period":"6month","weight":0.1111},{"period":"1year","weight":0.1921},{"period":"ytd","weight":0.1232}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company also develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The Company was incorporated in 2017 and is headquartered in Boulder, Colorado.","yearOnYearQuotes":[{"month":1,"riseRate":0.8,"avgChangeRate":0.169596},{"month":2,"riseRate":0.2,"avgChangeRate":-0.053086},{"month":3,"riseRate":0.4,"avgChangeRate":-0.097717},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.044897},{"month":5,"riseRate":0.5,"avgChangeRate":-0.020981},{"month":6,"riseRate":0.5,"avgChangeRate":-0.010487},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.007411},{"month":8,"riseRate":0.666667,"avgChangeRate":0.010346},{"month":9,"riseRate":0.6,"avgChangeRate":0.09895},{"month":10,"riseRate":0.6,"avgChangeRate":0.092429},{"month":11,"riseRate":0.4,"avgChangeRate":0.07088},{"month":12,"riseRate":0.2,"avgChangeRate":0.087485}],"exchange":"NASDAQ","name":"Edgewise Therapeutics, Inc.","nameEN":"Edgewise Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Edgewise Therapeutics, Inc.(EWTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Edgewise Therapeutics, Inc.(EWTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Edgewise Therapeutics, Inc.,EWTX,Edgewise Therapeutics, Inc.股票,Edgewise Therapeutics, Inc.股票老虎,Edgewise Therapeutics, Inc.股票老虎国际,Edgewise Therapeutics, Inc.行情,Edgewise Therapeutics, Inc.股票行情,Edgewise Therapeutics, Inc.股价,Edgewise Therapeutics, Inc.股市,Edgewise Therapeutics, Inc.股票价格,Edgewise Therapeutics, Inc.股票交易,Edgewise Therapeutics, Inc.股票购买,Edgewise Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Edgewise Therapeutics, Inc.(EWTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Edgewise Therapeutics, Inc.(EWTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}